Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13617
Title: | Long-acting therapeutics: development strategies and clinical significance |
Authors: | Jindal, Anil B. |
Keywords: | Pharmacy HIV/AIDS Tuberculosis Malaria parasite |
Issue Date: | Dec-2023 |
Publisher: | Elsevier |
Abstract: | High dosing frequency poses a considerable challenge in treating chronic conditions. This often results in missed doses, ultimately leading to therapy failure. Formulations capable of maintaining a prolonged plasma drug concentration, preferably spanning weeks to months or even years, are highly desirable. Long-acting therapeutics have emerged as a significant improvement in the treatment of chronic diseases. Recently, long-acting formulations have demonstrated substantial potential in preventing and treating chronic infections such as HIV/AIDS, tuberculosis, and malaria. Long-acting antiretroviral formulations have received approval from the USFDA for both preexposure prophylaxis and the treatment of HIV/AIDS. Moreover, ongoing extensive research is exploring the potential of long-acting formulations for treating tuberculosis and malaria, promising the eventual availability of LATs for these diseases in the market. |
URI: | https://www.sciencedirect.com/science/article/pii/S0169409X23004787?via%3Dihub http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13617 |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.